Search clinical trials for: Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)

Total 893 results

Sun Yat-sen University

Recruiting

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Nasopharyngeal Carcinoma

China
Fudan University

Recruiting

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

China
Eye & ENT Hospital of Fudan University

Active, not recruiting

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Chemotherapy | Immunotherapy | Hypopharyngeal Carcinoma

China
China Medical University, China

Terminated

A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer

Stomach Neoplasms

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Terminated

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Peking University; Zhejiang Cancer Hospital; Xiangya Hospital of Central South... and other collaborators

Not yet recruiting

Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC (NX-NPC)

Nasopharyngeal Carcinoma

China
The Christie NHS Foundation Trust
University College London Hospitals; University College, London; Royal Free Hospital...

Not yet recruiting

Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma (EMPHATIC)

Cholangiocarcinoma
Henan Provincial People's Hospital

Not yet recruiting

Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study (NSCLC)

Nsclc
The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China
Zhejiang Cancer Hospital

Recruiting

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Brain Metastases | NSCLC Stage IV | Immunotherapy

China
Shanghai Minimally Invasive Surgery Center

Suspended

A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer

Gastric Cancer

China
Hebei Medical University Fourth Hospital

Recruiting

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Cervical Cancer

China
Columbia University

Unknown

Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

Pancreatic Cancer Stage III | Pancreatic Cancer Stage II

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

Pancreatic Neoplasms

United States
Harbin Medical University

Not yet recruiting

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Rectal Cancer
Medical College of Wisconsin

Active, not recruiting

Magnetic Resonance (MR) Guided, Dose-Escalated Radiation Therapy (RT) + Chemotherapy in Pancreatic Cancer

Unresectable Pancreatic Cancer

United States
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Breast Cancer Metastatic

Taiwan
University of Southern California
Sanofi

Terminated

Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.

Pancreatic Cancer

United States
Eli Lilly and Company

Completed

Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents

Breast Neoplasms

France, Germany, Italy, Netherlands, Spain, United Kingdom
Harbin Medical University

Not yet recruiting

A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis

Lung Metastases | Colorectal Cancer Metastatic | Liver Metastases
Eli Lilly and Company

Completed

A Phase III Trial For Patients With Metastatic Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer of the Breast

United States, Argentina, Australia, Brazil, Korea, Republic of, Mexico, Puerto Rico, Taiwan
Yanqiao Zhang

Withdrawn

A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

Pancreatic Cancer | Liver Metastasis
Clinical Hospital Centre Zagreb

Active, not recruiting

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

Croatia
Columbia University
Sanofi

Completed

Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)

Metastatic Pancreatic Cancer

United States
Novartis Pharmaceuticals

Completed

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (RIGHT Choice)

Breast Cancer

India, Malaysia, Saudi Arabia, Taiwan, Russian Federation, Lebanon, South Africa, Thailand, Jordan, Turkey, Egypt, Vietnam, Singapore
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma

Gastric Cancer

China
Sun Yat-sen University

Unknown

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Shandong Cancer Hospital and Institute

Recruiting

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant Therapy | Resectable Lung Non-Small Cell Carcinoma | IMMUNOTHERAPY | Biomarkers / Blood

China
Tianjin Medical University Cancer Institute and...

Recruiting

Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma

Disease-free Survival Rate

China
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Withdrawn

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Carcinoma of Unknown Primary

United States
Columbia University

Completed

Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar

Pancreatic Cancer Stage IVA

United States
National Cancer Institute, Naples

Terminated

The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer (DISTAL-2)

Advanced Non-Small Cell Lung Cancer

Italy
Chinese PLA General Hospital

Recruiting

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Hodgkin Lymphoma | Anti-PD-1 Antibody Resistant

China
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Third Affiliated Hospital, Sun Yat-Sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Locally Advanced Gastric Cancer

China
Hebei Medical University Fourth Hospital

Not yet recruiting

To Explore the Efficacy of Hypofractionated Radiotherapy Followed by AG Regimen Chemotherapy Plus Camrelizumab Immunotherapy as Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer

Pancreatic Cancer

China
Zhejiang Cancer Hospital
Zhejiang Provincial People's Hospital; Jinhua Municipal Central Hospital; Huizhou... and other collaborators

Not yet recruiting

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

Esophageal Cancer

China
Eye & ENT Hospital of Fudan University
Chinese Academy of Medical Sciences

Recruiting

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Asan Medical Center

Completed

Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer

Pancreatic Cancer

Korea, Republic of
Academy Military Medical Science, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer

Advanced Breast Cancer
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

China
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Advanced Cervical Cancer

China
Zhenzhen Liu

Recruiting

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer | Camrelizumab

China
Fudan University
Nanfang Hospital of Southern Medical University; Ningbo Medical Center Lihuili... and other collaborators

Recruiting

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)

Head and Neck Cancer | Esophageal Squamous Cancer

China
Columbia University

Terminated

GTX Regimen for Biliary Cancers

Biliary Cancer

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Not yet recruiting

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Breast Cancer

China

3

Subscribe